Jefferies Financial Group Initiates Coverage on Beta Bionics (NASDAQ:BBNX)

Key Points

• Jefferies initiated coverage of Beta Bionics with a Buy rating and a $30 price target, implying approximately 68% upside from the prior close. The analyst consensus remains “Moderate Buy,” with an average target of $24.
• Beta Bionics reported quarterly revenue of $32.01 million and an adjusted loss of $0.53 per share, beating estimates of a $0.62 loss; analysts expect a full-year loss of $2.02 per share.
• Investors face notable risks, including recent insider selling and proposed securities-fraud litigation tied to disclosures about FDA compliance and the iLet automated insulin-delivery system.

Equities research analysts at Jefferies Financial Group began coverage on shares of Beta Bionics (NASDAQ:BBNX - Get Free Report) in a research note issued on Monday, MarketBeat reports. The brokerage set a "buy" rating and a $30.00 price target on the stock. Jefferies Financial Group's price target suggests a potential upside of 67.97% from the company's previous close.

Several other analysts also recently commented on the stock. UBS Group reaffirmed a "buy" rating and set a $25.00 price objective on shares of Beta Bionics in a research report on Tuesday, September 15th. Weiss Ratings upgraded shares of Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 18th. Truist Financial boosted their target price on shares of Beta Bionics from $23.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, September 24th. Wells Fargo & Company assumed coverage on shares of Beta Bionics in a research note on Wednesday, September 23rd. They set an "overweight" rating and a $28.00 target price on the stock. Finally, Barclays assumed coverage on shares of Beta Bionics in a report on Tuesday, October 6th. They issued an "overweight" rating and a $30.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Beta Bionics currently has an average rating of "Moderate Buy" and an average target price of $24.00.

Beta Bionics Price Performance

NASDAQ BBNX opened at $17.86 on Monday. The business has a 50 day simple moving average of $18.85 and a 200 day simple moving average of $15.06. Beta Bionics has a one year low of $8.80 and a one year high of $32.71. The stock has a market capitalization of $803.52 million, a P/E ratio of -10.82 and a beta of 3.39.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. The business had revenue of $32.01 million during the quarter. Equities analysts expect that Beta Bionics will post -2.02 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Christy Jones sold 6,430 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $23.00, for a total value of $147,890.00. Following the transaction, the director directly owned 19,564 shares in the company, valued at $449,972. This trade represents a 24.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mike Mensinger sold 4,375 shares of Beta Bionics stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $83,606.25. Following the completion of the sale, the insider directly owned 180,040 shares of the company's stock, valued at approximately $3,440,564.40. The trade was a 2.37% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 97,697 shares of company stock valued at $1,907,034. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Beta Bionics

A number of hedge funds have recently added to or reduced their stakes in BBNX. BlackRock Inc. bought a new stake in Beta Bionics during the 2nd quarter worth approximately $52,340,000. Eversept Partners LP raised its stake in shares of Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company's stock worth $14,177,000 after purchasing an additional 736,576 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in shares of Beta Bionics by 39.8% in the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company's stock valued at $8,446,000 after purchasing an additional 240,000 shares in the last quarter. 12 West Capital Management LP bought a new position in shares of Beta Bionics in the fourth quarter valued at approximately $17,520,000. Finally, Bruce & Co. Inc. bought a new position in shares of Beta Bionics in the first quarter valued at approximately $5,518,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: A trading report noted that BBNX shares increased approximately 3.8%, suggesting some short-term buying interest. However, the report did not identify a new fundamental catalyst or change to the company’s outlook. Beta Bionics Shares Up 3.8% - Still a Buy?
• Neutral Sentiment: Several law firms reminded investors that November 3, 2026 is the deadline to seek appointment as lead plaintiff in a proposed securities class action covering purchases made from July 30, 2025, through February 24, 2026. These notices are directed at investors who may have suffered losses and do not establish that Beta Bionics is liable. Rosen securities class action deadline notice
• Negative Sentiment: The proposed securities-fraud litigation alleges that investors were harmed by disclosures concerning FDA compliance and alleged FDA concerns involving Beta Bionics’ automated insulin-delivery system, the iLet. The notices state that related revelations previously caused sharp declines in the stock. The litigation creates potential legal costs, reputational risk and an overhang for BBNX until the allegations and regulatory issues are clarified. Beta Bionics securities fraud class action and iLet FDA compliance

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company's dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person's body weight and meal announcements as key inputs.